PTD-DBM

Contains a protein transduction domain enabling intracellular delivery. Disrupts Dishevelled-Axin protein interaction, preventing β-catenin degradation and activating Wnt target genes essential for hair follicle cycling and new follicle neogenesis.

PTD-DBM is a synthetic peptide combining a protein transduction domain (PTD) with a Dishevelled-binding motif (DBM) derived from the CXXC5 protein, engineered to penetrate cells and disrupt the CXXC5-Dishevelled protein-protein interaction that normally suppresses Wnt/beta-catenin signaling, with the goal of reactivating the Wnt pathway in hair follicle stem cells to promote follicle cycling and hair regrowth in androgenetic alopecia. The proposed mechanism targets a specific negative regulatory checkpoint: CXXC5 binds Dishevelled to prevent beta-catenin nuclear translocation; the PTD-DBM peptide competitively disrupts this interaction to restore Wnt pathway activity in follicular dermal papilla cells, a mechanism demonstrated to stimulate hair follicle activation in preclinical mouse models of hair loss. No published human clinical trials, pharmacokinetic studies, or Phase 1 safety data for PTD-DBM have been indexed in PubMed; available indexed literature consists of preclinical cell-based and mouse studies examining the CXXC5/Wnt/DHT signaling axis in androgenetic alopecia, with no human data characterizing this compound's safety, bioavailability, or efficacy. PTD-DBM has no FDA approval or approved indication in any jurisdiction; it is a research compound with a well-defined preclinical mechanistic rationale targeting the Wnt pathway but no published human data, and its development status as a clinical candidate has not been established in the indexed scientific literature.